Inhalable Formulations

A technology of excipients and active agents, applied in the field of inhalable preparations, can solve the problem of uneven dosage of content isolation

Inactive Publication Date: 2012-12-05
THE UNIV OF SYDNEY
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Unpredictable or preferential adhesion of one API to lactose over the other, combined with self-aggregation of one or both drugs, can result in content segregation and uneven dosing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalable Formulations
  • Inhalable Formulations
  • Inhalable Formulations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0174] The following description describes the method of forming particles of the invention from mannitol and an active agent selected from budesonide / fluticasone propionate and formoterol fumarate dihydrate / salmeterol xinafoate. It should be understood that other ingredients, including other active agents and / or other excipients, such as other sugars, can be used to form suitable carrier particles.

[0175] The particles formed herein can be used to form compositions suitable for inhalation by patients in need of such medicaments. This drug can be indicated for the treatment of respiratory conditions such as cystic fibrosis, COPD, bronchitis, allergies, nasopharynx and asthma. It should also be understood that such drugs can be adapted for use in the treatment of non-pulmonary conditions via pulmonary delivery.

[0176] Respirable Particles - Aerodynamic Diameter

[0177] The following information envisions demonstrating how aerodynamic diameter can be determined. This p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
sizeaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Respirable inhalable particles comprising active agent(s) and excipients in at least a partially crystalline form and their uses thereof.

Description

technical field [0001] The present invention relates to inhalable formulations, processes for producing such inhalable formulations and pharmaceutical compositions containing such inhalable formulations. Background technique [0002] The drug therapy of dry powder inhalation (DPI) has been used for many years to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD), bronchitis, allergies, rhinitis and asthma. Compared to oral drug intake, only relatively small doses are required for effective treatment because first-pass metabolism is significantly reduced. Small doses of this drug reduce the body's exposure to the drug and minimize side effects. Systemic adverse effects are also reduced due to local pulmonary delivery of drug uptake directly to the site of action. Lower dosage regimens, especially when expensive therapeutic drugs are a concern, may also offer considerable cost savings. There is now increasing interest in the use of pulmonary dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K31/573A61P11/06A61K31/569A61P11/00A61P11/08
CPCA61K31/137A61K31/167A61K31/57A61K31/573A61K31/58A61K9/0075A61K31/569A61P11/00A61P11/06A61P11/08A61K2300/00
Inventor 哈克-金·克翰保罗·扬丹尼拉·特拉伊尼菲利普·凯·利普·夸克穴田道子
Owner THE UNIV OF SYDNEY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap